2:1 for new genomic techniques
At the end of December, genetic engineering sceptics celebrated that the Council of Agriculture Ministers narrowly failed to reach a qualified...
Biovian and 3P Biopharmaceuticals join forces to create 3PBIOVIAN
Finnish Biovian Oy and Pamplona-based 3P Biopharmaceuticals Srl have joined forces to build a pan-European Contract Development and Manufacturing...
Roche jumps ship on AC Immune
In recent trials, both Semorinemab, a monoclonal antibody (mAb) binding all forms of Tau, and Crenezumab, a mAb targeting multiple forms of misfolded...
Amsilk partners with 21st.BIO
Advanced materials specialist AMSilk GmbH (Neuried, Germany) and biotech production specialst 21st.BIO (Copenhagen) have announced to join forces to...
Novozymes and Chr. Hansen Complete Merger, Forming Novonesis
In a significant development in the biosolutions sector, Novozymes A/S and Chr. Hansen Holding A/S successfully completed their merger, forming a new...
Researcher find potential target for atherosclerosis
Researchers have found a new way to reverse atherosclerotic plaque formation at the early stages. In Nature Cardiovascular Research, Alma...
£26m for Cystic Fibrosis Drug Trial
With funding led by Panakes Partners and involvement from current investors, Enterprise Therapeutics Ltd. has received £26m (~€30.5m) for the Phase...